BioStock: Elicera well-positioned to thrive in 2022

The immuno-oncology company Elicera Therapeutics achieved significant accomplishment in 2021, e.g., a listing on Nasdaq First North Growth Market and raising of 62 MSEK before issue costs, making Elicera well equipped to take yet another step in its development of cancer immunotherapies. BioStock reached out to Elicera’s CEO Jamal El-Mosleh to get his thoughts on the company’s achievements during 2021 and his expectations for 2022.

Read the interview with Elicera's CEO Jamal El-Mosleh at biostock.se:

https://www.biostock.se/en/2022/01/elicera-well-positioned-to-thrive-in-2022/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se